Company news

Xeris Biopharma Holdings, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta Bionics

May 5, 2024

Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement With Beta Bionics

May 5, 2024

Xeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024

May 1, 2024

Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conference

April 1, 2024

Xeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capital

March 5, 2024

Xeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Events

March 5, 2024

Xeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024

February 27, 2024

Xeris to Present at the Oppenheimer 34th Annual Healthcare Life Science Conference

February 4, 2024

Xeris Biopharma Enters Into an Exclusive Worldwide License Agreement for Xeriject® Formulation of Teprotumumab

January 9, 2024

Xeris Biopharma Updates Its Outlook for 2023

January 3, 2024

Xeris Biopharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference

December 26, 2023

Xeris Biopharma Reports Third Quarter 2023 Financial Results

November 8, 2023

Xeris Biopharma Raises Full-Year Financial Guidance and Reaffirms Cash Flow Breakeven in Q4 2023

October 15, 2023

Xeris Biopharma Announces Private Convertible Note Exchange Transactions

September 26, 2023

Xeris to Participate in the 2023 Cantor Global Healthcare Conference

September 13, 2023

Xeris to Participate at the H.C. Wainwright 25th Annual Global Investment Conference

August 27, 2023

Xeris Biopharma Reports Second Quarter 2023 Financial Results

August 7, 2023

Xeris Biopharma to Report Second Quarter 2023 Financial Results on August 8, 2023

July 31, 2023

Xeris Ships One Millionth Gvoke® Unit

July 30, 2023

Xeris Biopharma reaches Phase 2 milestone by dosing first participant in hypothyroidism study

June 21, 2023

Xeris Biopharma Announces First Participant Dosed in a Phase 2 Clinical Study of Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121) in Patients With Hypothyroidism

June 20, 2023

Xeris Pharmaceuticals shares latest product and partnership updates

June 18, 2023

Xeris Biopharma to Participate at the Jefferies Healthcare Conference

May 31, 2023

Xeris Biopharma Reports First Quarter 2023 Financial Results

May 8, 2023

Xeris Biopharma to Report First Quarter 2023 Financial Results on May 9, 2023

May 1, 2023

Xeris Biopharma Announces Issuance of U.S. Patent Covering XeriSol™ Formulations

April 17, 2023

Xeris Biopharma enters research collaboration with Regeneron Pharmaceuticals to advance XeriJect

April 4, 2023

Xeris Biopharma Announces Research Evaluation Collaboration and Option Agreement With Regeneron for XeriJect™

March 29, 2023

Xeris Biopharma Appoints Ricki Fairley to Board of Directors

March 28, 2023

Xeris Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides 2023 Financial Guidance

March 7, 2023

Xeris Biopharma to Report Fourth Quarter and Full-Year 2022 Financial Results on March 8, 2023

February 22, 2023

Xeris Biopharma to Participate in the SVB Securities Global Biopharma Conference 2023

February 1, 2023

Xeris Biopharma Announces FDA Grants Orphan-drug Exclusivity for Recorlev®

January 29, 2023

Xeris Biopharma Updates Its Outlook For 2022

January 4, 2023

Xeris Biopharma to Present at 41st Annual J.P. Morgan Healthcare Conference

January 4, 2023

Xeris Biopharma Announces Plans for a Phase II Dose-Finding Study for Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121) as Replacement Therapy for Hypothyroidism

December 14, 2022

Xeris Biopharma Announces Research Collaboration and Option Agreement With Horizon Therapeutics plc for XeriJect™ Formulation of Teprotumumab

November 22, 2022

Xeris Biopharma Reports Third Quarter 2022 Financial Results and Recent Events

November 8, 2022

Xeris Biopharma to Report Third Quarter 2022 Financial Results on November 9, 2022

November 1, 2022

Xeris Biopharma Announces Results of the Extended Evaluation of Recorlev® (Levoketoconazole) From the Phase 3 Sonics Study Published in the European Journal of Endocrinology

October 31, 2022

Xeris Biopharma Announces Positive Topline Phase 1 Clinical Data of Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121); Hosts Conference Call and Webcast

October 19, 2022

Xeris Biopharma Reports Second Quarter Financial Results and Upcoming Events

August 9, 2022

Xeris Biopharma to Report Second Quarter 2022 Financial Results on August 10, 2022

August 2, 2022

Xeris’ Commercialization Partner for Ogluo®, Tetris Pharma Ltd, to Be Acquired by Arecor Therapeutics

July 31, 2022

Xeris Announces Full Results From the Logics Study of Recorlev® and Presentation of New Burden of Illness in Cushing’s Syndrome Data at AACE Annual Meeting May 12-14

May 11, 2022

Xeris Biopharma Reports First Quarter Financial Results and Upcoming Events

May 10, 2022

Xeris Biopharma to Report First Quarter 2022 Financial Results on May 11, 2022

May 3, 2022

Xeris Biopharma Announces Gvoke® Kit Is Now Available for the Treatment of Severe Hypoglycemia in Adults and Children With Diabetes Ages 2 And Above

March 15, 2022

Xeris Biopharma Reports Fourth Quarter and Full-year 2021 Financial Results and Recent Events

March 9, 2022

Xeris Announces $150M Senior Secured Term Loan Facility With Hayfin Capital

March 9, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 22 calls. Every call is listed under its year.

Decks